Erythromelalgia during Infliximab Induction Therapy for Ulcerative Colitis: A Case Report and Literature Review

Background: Erythromelalgia is a rare neurovascular disorder characterised by episodes of burning pain and erythema of the extremities. Secondary forms are mainly associated with myeloproliferative neoplasms, autoimmune diseases and drugs. To our knowledge, only two cases attributed to anti-tumour necrosis factor (TNF) alpha therapy have been published, both in patients with Crohn's disease. Case Presentation: A 19-year-old student whose ulcerative colitis presented as acute severe colitis received corticosteroids and mesalazine, followed by induction therapy with infliximab. One week after the second infusion, during corticosteroid tapering, she developed intense burning pain and tingling of both feet, relieved only by prolonged immersion in ice water. All treatments were stopped. Examination showed bilateral oedema, a symmetrical erythema extending to the lower legs and papules, some of which were ulcerated. Blood count, vitamin B levels, thyroid function, HIV serology, immunological tests and electroneuromyography were normal, and there was no diabetes mellitus. Erythromelalgia secondary to infliximab was diagnosed and reported to pharmacovigilance. Pregabalin was partially effective; switching to gabapentin resolved pain and erythema within one week. Treatment was tapered from the fourth month, another anti-TNF agent was later introduced, and no recurrence occurred after eight months. Conclusion: Erythromelalgia is a rare neurocutaneous adverse event of anti-TNF agents. Purpura or ulceration should prompt the exclusion of a drug-induced vasculitis and of cold-induced skin injury. Early recognition allows symptomatic treatment and guides the choice of the next biologic.

Authors

Institutions

Publication Details

Published
2026-11-19
DOI
https://doi.org/10.9734/ajrdes/2026/v9i1195
Primary Topic
Inflammatory Bowel Disease
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Erythromelalgia during Infliximab Induction Therapy for Ulcerative Colitis: A Case Report and Literature Review

Nadia Ismaïli, Mariame Meziane, Laïla Benzekri, Syrine Hamada
Inflammatory Bowel Disease
article

Erythromelalgia during Infliximab Induction Therapy for Ulcerative Colitis: A Case Report and Literature Review

Nadia Ismaïli, Mariame Meziane, Laïla Benzekri, Syrine Hamada
article en

Abstract

Background: Erythromelalgia is a rare neurovascular disorder characterised by episodes of burning pain and erythema of the extremities. Secondary forms are mainly associated with myeloproliferative neoplasms, autoimmune diseases and drugs. To our knowledge, only two cases attributed to anti-tumour necrosis factor (TNF) alpha therapy have been published, both in patients with Crohn's disease. Case Presentation: A 19-year-old student whose ulcerative colitis presented as acute severe colitis received corticosteroids and mesalazine, followed by induction therapy with infliximab. One week after the second infusion, during corticosteroid tapering, she developed intense burning pain and tingling of both feet, relieved only by prolonged immersion in ice water. All treatments were stopped. Examination showed bilateral oedema, a symmetrical erythema extending to the lower legs and papules, some of which were ulcerated. Blood count, vitamin B levels, thyroid function, HIV serology, immunological tests and electroneuromyography were normal, and there was no diabetes mellitus. Erythromelalgia secondary to infliximab was diagnosed and reported to pharmacovigilance. Pregabalin was partially effective; switching to gabapentin resolved pain and erythema within one week. Treatment was tapered from the fourth month, another anti-TNF agent was later introduced, and no recurrence occurred after eight months. Conclusion: Erythromelalgia is a rare neurocutaneous adverse event of anti-TNF agents. Purpura or ulceration should prompt the exclusion of a drug-induced vasculitis and of cold-induced skin injury. Early recognition allows symptomatic treatment and guides the choice of the next biologic.

Vol. 9(1)
Mohammed V University (MA)
Inflammatory Bowel Disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon